Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
2019
Ashraf, Yahya | Mansouri, Hanane | Laurent-Matha, Valérie | Alcaraz, Lindsay, | Roger, Pascal | Guiu, Séverine | Derocq, Danielle | Robin, Gautier | Michaud, Henri-Alexandre | Delpech, Helène | Jarlier, Marta | Pugnière, Martine | Robert, Bruno | Puel, Anthony | Martin, Lucie | Landomiel, Flavie | Bourquard, Thomas | Achour, Oussama | Fruitier-Arnaudin, Ingrid | Pichard, Alexandre | Deshayes, Emmanuel | Turtoi, Andrei | Poupon, Anne | Simony-Lafontaine, Joëlle | Boissière-Michot, Florence | Pirot, Nelly | Bernex, Florence | Jacot, William | Du Manoir, Stanislas | Theillet, Charles | Pouget, Jean-Pierre | Navarro-Teulon, Isabelle | Bonnefoy, Nathalie | Pèlegrin, André | Chardès, Thierry | Martineau, Pierre | Liaudet-Coopman, Emmanuelle
Background: Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumorspecific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC.
Mostrar más [+] Menos [-]Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Institut national de la recherche agronomique
